RxSight, Inc.

Stage 4 · Declining · week 3

As of Oct 22, 2026, RxSight is in Stage 4, the downtrend phase, now in week 3 (since Oct 6, 2026). It closed at $5.08, 61.2% below its 52-week high and below its 200-day average, which is falling.

$5.08

+3.67% today

$211M · Micro cap

Market Neutral — Building

Pro read

Pro

Our read

Declining, below its long-term trend

Setup score

—

Momentum

Steady

Edge

—

Is RXST early, or has it already run? Pro answers that for every US stock we cover, after every close.

Get Pro · $19 a month

Renews monthly until you cancel. Cancel any time in Plan & billing.

Loading price chart…

Stage Cycle Timeline2023-08-16 → 2026-10-22

S2 32w

S4 48w

S1 16w

S4 26w

2023-08-162026-10-22

S1S2S3S4Setup score (0–10, dashed line at 5)

S2 6w → S3 10w → S2 32w → S3 8w → S4 3w → S1 4w → S4 48w → S1 16w → S2 1w → S4 26w → S1 8w → S4 2w current

Total tracked: 165 weeks across 12 stage runs.

RXST among Medical Devices83rd of 141 by relative strength

All 141 →

Stocks in Medical Devices ranked by relative strength, with stage and one-month change
#	Stock	Stage	RS	1M
1	TXG10x Genomics, Inc.	Stage 2 · wk 48	99	−7.8%
2	RCELAvita Medical, Inc.	Stage 2 · wk 13	98	+40.8%
3	BFLYButterfly Network, Inc. Class A	Stage 2 · wk 26	98	−26.0%
4	HAEHaemonetics Corporation	Stage 2 · wk 17	96	+8.7%
5	GKOSGlaukos Corporation	Stage 2 · wk 25	96	+15.1%
6	AXGNAxogen, Inc.	Stage 3 · wk 2	95	−15.3%
7	NEOGNeogen Corporation	Stage 2 · wk 14	95	−11.7%
8	BVSBioventus Inc. Class A	Stage 2 · wk 15	95	+10.5%
…83	RXSTRxSight, Inc.	Stage 4 · wk 3	27	+4.7%

vs 52W High

-61.2%

$4.51 lo$13.09 hi

61.2% below 52W high, deep Stage 4 damage

In Stage 4, distance from the 52-week high reflects an ongoing decline, not a discount.

Stage Maturity

Week 3

1w13w26w

Week 3, early Stage 4 decline

How long this stock has been in Stage 4 decline. The longer the downtrend, the more entrenched the selling pressure. No length of decline marks a bottom on its own.

vs 200 DMA

-21.9%

200 DMA: $6.51 · sloping down

In Stage 4, the stock is below its 200-day average, the hallmark of a downtrend. Stage analysis waits for that to reverse before buying.

Rel Volume

0.51x

vs 50-day avg

High volume on down days in Stage 4 confirms institutional selling. Low-volume bounces are typical. They lack real buyers and are easy to mistake for reversals.

Trend Health

↓

Short-term trend rolling over

Two reads of momentum. The arrow shows the direction of the short-term trend: rising (↑ or ↗), flat (→) or rolling over (↓). The ⇈ mark appears when our trend model reads the move as gaining speed on top of the longer trend. Strongest when both agree.

+4.7%

-2.1%

-29.4%

YTD

-51.1%

-41.7%

Scan Membership

Breakout Watch

Latest: 2023-12-07

3 appearances in last 60 days. First seen: 2022-06-03.

A stock that keeps qualifying week after week does so because its Stage 2 structure keeps holding. Staying power in the scan says more about the trend than any single appearance.

Recent Stage Timeline

2026-10-22S4

Wk 3 · Vol 0.51x

2026-10-21S4

Wk 3 · Vol 0.57x

2026-10-20S4

Wk 3 · Vol 0.56x

2026-10-19S4

Wk 2 · Vol 0.92x

2026-10-16S4

Wk 2 · Vol 1.28x

2026-10-15S4

Wk 2 · Vol 0.74x

2026-10-14S4

Wk 2 · Vol 1.01x

2026-10-13S4

Wk 2 · Vol 0.84x

2026-10-12S4

Wk 1 · Vol 1.02x

2026-10-09S4

Wk 1 · Vol 0.64x

2026-10-08S4

Wk 1 · Vol 1.14x

2026-10-07S4

Wk 1 · Vol 1.01x

Moving averages & range

50 DMA

$5.58

200 DMA

$6.51

52W High

$13.09

52W Low

$4.51

5D Low

$4.51

Resistance levels (recent highs)

20d High

$5.08

60d High

$7.33

120d High

$7.38

250d High

$13.09

Next resistance

+44.3%

to 60d High

ROE

-17.3%

Profit margin -36.8%

Dividend Yield

0.00%

P/B 0.8

RxSight: quick answers

What stage is RxSight in?

As of Oct 22, 2026, RxSight (RXST) is in Stage 4, the downtrend phase. It entered Stage 4 on Oct 6, 2026 and is in week 3. What the four stages mean

Is RxSight in an uptrend?

No. RxSight is in a Stage 4 downtrend. It trades 21.9% below its 200-day average, which is falling.

How far is RxSight from its 52-week high?

RxSight closed at $5.08 on Oct 22, 2026, 61.2% below its 52-week high of $13.09. Its 52-week low is $4.51.

How has RxSight performed over the past year?

As of Oct 22, 2026, RxSight is down 41.7% over the past year and down 51.1% so far in 2026.

Which sector and industry is RxSight in?

RxSight is in the Medical Devices industry, part of the Health Care sector.

About this companyHealth Care· Medical Devices

RxSight, Inc., a commercial-stage medical technology company, engages in the research and development, manufacture, and sale of light adjustable intraocular lenses (LAL) used in cataract surgery in the United States. It offers RxSight system that enables doctors to customize and enhance the visual acuity for patients after cataract surgery. The company's RxSight system includes RxSight Light Adjustable Lens (LAL), an intraocular lens made of photosensitive material that changes shape in response to specific patterns of ultraviolet, which can be adjusted to improve uncorrected visual acuity; and RxSight light delivery device, an office-based light treatment device that delivers UV light in a programmed pattern to modify the LAL based on the visual correction needed to achieve desired vision after cataract surgery. RxSight, Inc. was formerly known as Calhoun Vision, Inc. and changed its name to RxSight, Inc. in February 2017. The company was incorporated in 1997 and is headquartered in Aliso Viejo, California.

Visit company website →

All analytics based on EOD data. Data as of 2026-10-22. Past data patterns are not indicative of future results. This page is a data analytics tool only.